NCT04368507 2022-11-14To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer PatientsCellabMEDPhase 1/2 Completed35 enrolled